The Food and Drug Administration has approved encorafenib (Braftovi) in combination with cetuximab (Erbitux) to treat adults with metastatic colorectal cancer whose tumors have a specific mutation in the BRAF gene, called V600E.
from Cancer Currents: An NCI Cancer Research Blog https://ift.tt/2SQlAJI
from Cancer Currents: An NCI Cancer Research Blog https://ift.tt/2SQlAJI